Elsevier

Pharmacological Research

Volume 72, June 2013, Pages 35-44
Pharmacological Research

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants

https://doi.org/10.1016/j.phrs.2013.03.007Get rights and content

Abstract

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in subjects with non-dialysis-dependent CKD resulted in a marked reduction in death from all causes (relative risk [RR]: 0.66; 95% confidence interval [CI]: 0.55–0.79; p < 0.0001), cardiac causes (RR: 0.69; 95%CI: 0.55–0.68; p = 0.0012), cardiovascular events (RR: 0.55; 95%CI: 0.4–0.75; p = 0.0001) and stroke (RR: 0.66; 95%CI: 0.5–0.88; p = 0.0022). The use of statins in dialysis-dependent CKD patients resulted in a non-significant effect on death from all causes (RR: 0.99; 95%CI: 0.88–1.11; p = 0.85) and stroke (RR: 1.31; 95%CI: 0.9–1.89; p > 0.05), but had the effect of reducing death from cardiac causes (RR: 0.79; 95%CI: 0.64–0.98; p < 0.05) and cardiovascular events (RR: 0.81; 95%CI: 0.7–0.94; p < 0.05). In conclusion, the use of statins should be indicated in cardiovascular disease prevention especially in patients with non-dialysis-dependent CKD. According to the very limited data the obtained results suggest caution in expecting a reduction in cardiovascular events in patients on dialysis.

Introduction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality not only among the general population, but also in patients with chronic kidney disease (CKD) [1]. Several clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are gaining widespread acceptance as a principal therapy for the primary and secondary prevention of atherosclerosis and CVD [2], [3], [4]. The role of statins in primary prevention of CVD risk in CKD patients still remains to be clarified. No large randomized clinical trials have provided evidence that statins as a primary prevention strategy reduce CVD in these patients. It has been suggested that these agents are effective and appear safe for secondary prevention of cardiovascular (CV) events in individuals with mild chronic renal insufficiency (especially stages 1–3 of CKD) [5], [6].

There are potential explanations for the putative effects of statins on the rate of CV events in patients with CKD. Statins may exert their protection against kidney disease through a variety of immunomodulatory effects [3], [4], [5], [6]. Statin therapy attenuates endothelial dysfunction, enhances renal perfusion and reduces abnormal permeability to plasma proteins [7]. In experimental models, statins have been shown to inhibit the progression of renal damage, but in humans there are only observational studies, which do not provide definite information [8].

In several animal models, the beneficial effects of statins on renal disease associated with hypertension and vascular injury have been described [8], [9]. Moreover, in a rat model of glomerulonephritis statin treatment prevented macrophage glomerular infiltration and suppressed mesangial cell proliferation and mesangial matrix expansion [10]. In consideration of the anti-inflammatory effects on vascular structure, regardless of cholesterol reduction, statins have experimentally been demonstrated to attenuate tumor necrosis factor-α induced angiogenesis in vitro and reverse myocardial expression of inflammatory and growth factors [11]. The inhibition of inflammatory cytokine-induced vascular endothelial growth factor expression was hypothesized [11]. Some investigators postulate that the benefit of statin therapy in patients with CKD is attributable to better kidney perfusion secondary to improved endothelial and cardiac function and improved protein trafficking in the glomerulus and proximal tubular epithelium [12].

Meta-analyses and post hoc analyses have reported benefits of statins for all-cause and CV mortality in CKD patients [13], [14]. It has been suggested that the absolute benefit of treatment with statins seems to be greater among individuals with non-dialysis-dependent CKD. Studies in end-stage renal disease (ESRD) patients on dialysis yielded conflicting results and such positive effects were not found in the 4D (Die Deutsche Diabetes Dialyse) (expect from the fatal stroke and cardiac events) and AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) studies [15], [16]. Recently, however, the SHARP (Study of Heart and Renal Protection) study, despite its limitations (simvastatin + ezetimibe vs. placebo), showed an insignificant trend toward reducing CV events in dialysis patients [17]. Therefore, we performed a meta-analysis to evaluate the impact of statin therapy on CV events and death from all causes in patients with CKD.

Section snippets

Data sources

We searched PubMed, Web of Science (ISI), Cochrane Library, and Scopus using keywords such as statins, chronic kidney disease, chronic renal failure, hemodialysis, atorvastatin, lovastatin, pravastatin, simvastatin and rosuvastatin. We limited our search to randomized clinical trials written in English. Data were collected for the years 1966 to October 2012. Studies were chosen for the meta-analysis if they met the inclusion criteria including CKD, chronic renal failure, hemodialysis,

Results

The electronic searches yielded 667 items: 293 from PubMed, 63 from Web of Sciences, 300 from Scopus, and 11 from the Cochrane Library. Of these, 32 trials were scrutinized in the full text, of which 21 trials were considered unsuitable while 11 trials [14], [15], [16], [19], [20], [21], [22], [23], [24], [25], [26] were included in the analysis (Fig. 1). Of these 11 studies, 8 [14], [15], [16], [19], [23], [24], [25], [26] obtained a Jadad score of ≥3 and the others [20], [21], [22] gained a

Discussion

This meta-analysis is part of a group of meta-analyses assessing different aspects of the role of statins in patients with hypertension and its complications, including chronic kidney disease [5], [27]. In the present study, we gathered the reliable evidence available to date including 21,295 patients with non-dialysis and dialysis-dependent CKD from 11 randomized trials assessing the specific effect of statins on cardiovascular events and death from all causes [14], [15], [16], [19], [20], [21]

Conflict of interest statement

M.B. (Marcin Barylski), S.N., P.S., J.R., M.A. have no conflict of interest. D.P.M. has given talks, attended conferences and participated in trials and advisory boards sponsored by MSD, Genzyme and Abbott. P.P.T. has given talks for AbbVie, Amarin, Astra-Zeneca, Genzyme, Kowa, Merck and is consultant for Amgen, Atherotech, Genzyme, Kowa, Liposcience, Merck. K.K.R. has received honoraria for lectures or advisory boards from Pfizer, Astra-Zeneca, MSD, Roche, Novartis, Sanofi, Regeneron, Servier,

References (45)

  • M. Chonchol et al.

    Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency

    American Journal of Kidney Diseases

    (2007)
  • M.J. Koren et al.

    Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD

    American Journal of Kidney Diseases

    (2009)
  • H.M. Colhoun et al.

    Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)

    American Journal of Kidney Diseases

    (2009)
  • A. Poli et al.

    Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study

    Pharmacological Research

    (2011)
  • M. Banach et al.

    Time for new indications for statins?

    Medical Science Monitor

    (2009)
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    Lancet

    (1994)
  • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group

    New England Journal of Medicine

    (1998)
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

    Lancet

    (2002)
  • D. Nikolic et al.

    Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

    Current Medical Research and Opinion

    (2013)
  • J. Rysz et al.

    Nephroprotective and clinical potential of statins in dialyzed patients

    Expert Opinion on Therapeutic Targets

    (2009)
  • G. O’Driscoll et al.

    Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

    Circulation

    (1997)
  • W.F. Keane et al.

    The role of altered lipid metabolism in the progression of renal disease: experimental evidence

    American Journal of Kidney Diseases

    (1991)
  • Cited by (97)

    • Guidelines for the early evaluation and management of chronic kidney disease in China

      2023, Chinese Journal of Internal Medicine/Zhonghua Neike Zazhi
    View all citing articles on Scopus
    View full text